Imcivree

Setmelanotide, the active ingredient in Imcivree, is a melanocortin 4 receptor (MC4R) agonist presented as a 1 mg/mL injection solution (prefilled pen) for subcutaneous use. It treats obesity linked to specific genetic deficiencies, including POMC, LEPR, PCSK1, Bardet‑Biedl and Alström syndromes, in patients with confirmed diagnoses.

GNH USA supplies Imcivree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imcivree (setmelanotide) is indicated for rare genetic forms of obesity that involve the melanocortin‑4 receptor pathway.

- Obesity due to proopiomelanocortin (POMC) deficiency: reduces appetite and supports weight management in patients with confirmed POMC deficiency. - Obesity due to leptin receptor (LEPR) deficiency: improves weight outcomes in individuals with genetically confirmed LEPR deficiency. - Obesity due to proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency: aids weight control in patients with PCSK1 deficiency. - Obesity associated with Bardet‑Biedl syndrome: helps achieve weight reduction in patients with this ciliopathy‑related obesity. - Obesity associated with Alström syndrome: contributes to weight management in patients with Alström syndrome.

Common Side Effects: - Injection‑site pain or erythema. - Nausea or vomiting. - Diarrhea or abdominal discomfort. - Headache. - Fatigue. - Hyperpigmentation of the skin.

Serious or Rare Side Effects: - Severe hypersensitivity reactions, including anaphylaxis. - Persistent severe hyperpigmentation. - Significant cardiovascular events such as hypertension. - Acute pancreatitis. - Severe injection‑site infection requiring medical attention.

Imcivree requires careful monitoring due to its targeted mechanism and injectable form. - Pregnancy: safety unknown; avoid unless potential benefit justifies the risk. - Breastfeeding: unknown; consider discontinuation if infant exposure is a concern. - Renal impairment: monitor renal function and adjust therapy as needed. - Hypersensitivity: discontinue immediately if signs of an allergic reaction appear. - Monitoring: regularly assess weight, metabolic parameters, and skin pigmentation changes. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Setmelanotide may interact with other agents that influence appetite or the melanocortin pathway.

Major Interactions (Avoid): - Concomitant use of other MC4R agonists: risk of additive pharmacologic effects. - Live vaccines: potential alteration of immune response.

Moderate Interactions (Monitor Closely): - Hormonal therapies affecting appetite (e.g., glucocorticoids): monitor weight changes. - Strong CYP450 inhibitors or inducers: observe for any unexpected pharmacodynamic changes, although metabolism is minimal. - Immunosuppressants: watch for altered infection risk.